{
    "relation": [
        [
            "",
            "MK0518 200 mg b.i.d.",
            "MK0518 400 mg b.i.d.",
            "MK0518 600 mg b.i.d.",
            "Placebo"
        ],
        [
            "Description",
            "Optimized background antiretroviral therapy (OBT), if possible, based on screening genotypic/phenotypic resistance and past treatment history and MK0518 200 mg twice a day (b.i.d.). Once the Phase III dose was determined, all patients were switched to the Phase III dose (400 mg b.i.d.) after completion of at least 24 weeks double-blind therapy.",
            "OBT, if possible, based on screening genotypic/phenotypic resistance and past treatment history and MK0518 400 mg b.i.d.",
            "OBT, if possible, based on screening genotypic/phenotypic resistance and past treatment history and MK0518 600 mg b.i.d.. Once the Phase III dose was determined, all patients were switched to the Phase III dose (400 mg b.i.d.) after completion of at least 24 weeks double-blind therapy.",
            "OBT, if possible, based on screening genotypic/phenotypic resistance and past treatment history and MK0518 matching placebo b.i.d.. Once the Phase III dose was determined, all patients were switched to the Phase III dose (400 mg b.i.d.) after completion of at least 24 weeks double-blind therapy."
        ]
    ],
    "pageTitle": "Safety and Efficacy of an Investigational Drug in Human Immunodeficiency Virus (HIV)-Infected Patients Failing Current Antiretroviral Therapies (0518-005)(COMPLETED) - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT00105157?sect=Xi0156&view=results",
    "hasHeader": true,
    "headerPosition": "MIXED",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042987155.85/warc/CC-MAIN-20150728002307-00226-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 857135603,
    "recordOffset": 857119209,
    "tableOrientation": "HORIZONTAL",
    "TableContextTimeStampAfterTable": "{2288=Primary therapy period: 22-Apr-2005 to 09-Nov-2006}",
    "textBeforeTable": "Reporting Groups Patients failed prior antiretroviral therapy (HIV RNA >5000 copies/mL), and had documented resistance to at least one drug in each class of licensed oral antiretroviral therapy (Nucleoside Reverse Transcriptase inhibitors, Non-Nucleoside Reverse Transcriptase inhibitors and Protease Inhibitors). All patients must have met laboratory criteria. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details Primary therapy period: 22-Apr-2005 to 09-Nov-2006 Multicenter (31) in the United States (15) and outside the United States (16) Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Drug: Comparator: MK0518 Drug: MK0518 Drug: Placebo Interventions: HIV Infections Acquired Immunodeficiency Syndrome",
    "textAfterTable": "Participant Flow for 3 periods Period 1: \u00a0 Double-Blind (DB) \u00a0 \u00a0 MK0518 200 mg b.i.d. \u00a0 \u00a0 MK0518 400 mg b.i.d. \u00a0 \u00a0 MK0518 600 mg b.i.d. \u00a0 \u00a0 Placebo \u00a0 STARTED \u00a0 \u00a0 44 \u00a0 \u00a0 45 \u00a0 \u00a0 45 \u00a0 \u00a0 45 \u00a0 Treated \u00a0 \u00a0 43 \u00a0 \u00a0 45 \u00a0 \u00a0 45 \u00a0 \u00a0 45 \u00a0 COMPLETED \u00a0 \u00a0 30 \u00a0 \u00a0 31 \u00a0 \u00a0 33 \u00a0 \u00a0 6 \u00a0 NOT COMPLETED \u00a0 \u00a0 14 \u00a0 \u00a0 14 \u00a0",
    "hasKeyColumn": false,
    "keyColumnIndex": -1,
    "headerRowIndex": 0
}